NASDAQ:SABS - Nasdaq - US78397T2024 - Common Stock - Currency: USD
NASDAQ:SABS (5/28/2025, 4:10:58 PM)
1.76
-0.02 (-1.12%)
The current stock price of SABS is 1.76 USD. In the past month the price decreased by -0.55%. In the past year, price decreased by -32.58%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.83 | 323.41B | ||
AMGN | AMGEN INC | 13.41 | 149.70B | ||
GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
ONC | BEIGENE LTD-ADR | 6.16 | 25.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 22.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
BIIB | BIOGEN INC | 8.06 | 18.69B |
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Miami Beach, Florida and currently employs 63 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
SAB BIOTHERAPEUTICS INC
777 W 41St St, Suite 401
Miami Beach FLORIDA US
CEO: Samuel J. Reich
Employees: 63
Phone: 13058452813
The current stock price of SABS is 1.76 USD. The price decreased by -1.12% in the last trading session.
The exchange symbol of SAB BIOTHERAPEUTICS INC is SABS and it is listed on the Nasdaq exchange.
SABS stock is listed on the Nasdaq exchange.
10 analysts have analysed SABS and the average price target is 9.18 USD. This implies a price increase of 421.59% is expected in the next year compared to the current price of 1.76. Check the SAB BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SAB BIOTHERAPEUTICS INC (SABS) has a market capitalization of 16.35M USD. This makes SABS a Nano Cap stock.
SAB BIOTHERAPEUTICS INC (SABS) currently has 63 employees.
SAB BIOTHERAPEUTICS INC (SABS) has a support level at 1.78 and a resistance level at 1.86. Check the full technical report for a detailed analysis of SABS support and resistance levels.
The Revenue of SAB BIOTHERAPEUTICS INC (SABS) is expected to decline by -62.25% in the next year. Check the estimates tab for more information on the SABS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SABS does not pay a dividend.
SAB BIOTHERAPEUTICS INC (SABS) will report earnings on 2025-08-06, before the market open.
SAB BIOTHERAPEUTICS INC (SABS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.7).
The outstanding short interest for SAB BIOTHERAPEUTICS INC (SABS) is 1.28% of its float. Check the ownership tab for more information on the SABS short interest.
ChartMill assigns a technical rating of 2 / 10 to SABS. When comparing the yearly performance of all stocks, SABS is a bad performer in the overall market: 77.95% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to SABS. SABS may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months SABS reported a non-GAAP Earnings per Share(EPS) of -3.7. The EPS increased by 42.07% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -89.92% | ||
ROE | -160.11% | ||
Debt/Equity | 0.15 |
ChartMill assigns a Buy % Consensus number of 84% to SABS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 19.46% and a revenue growth -62.25% for SABS